Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MTI-301 |
| Synonyms | |
| Therapy Description |
MTI-301 inhibits SCD1 resulting in decreased fatty acid synthesis, which potentially induces tumor cell apoptosis, enhances antitumor immune response, and inhibits tumor growth (J Pharmacol Exp Ther 392, no. 3 (2025), NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MTI-301 | MTI 301|MTI301 | MTI-301 inhibits SCD1 resulting in decreased fatty acid synthesis, which potentially induces tumor cell apoptosis, enhances antitumor immune response, and inhibits tumor growth (J Pharmacol Exp Ther 392, no. 3 (2025), NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06911008 | Phase I | MTI-301 | MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers | Recruiting | USA | 0 |